At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patients are at the heart of everything we do, inspiring us, driving our scientiﬁc discovery, and leading us to rethink the patient experience.
Engaging patient and provider advocacy organizations is an important aspect of connecting with patients and other stakeholders to improve patient care throughout discovery, development, and delivery of solutions. Engagement with these organizations may relate to insights around drug development, disease experience, education and awareness, clinical trials, patient support programs, policy topics, and designing new initiatives and approaches to support the patient experience.
To ensure our relationships with patient and provider advocacy organizations are ethical and transparent,
we are guided by the following principles:
We are committed to open dialogue and transparent sharing of information with advocacy organizations to improve patient care.
We respect and encourage the independence of advocacy organizations. We will never require that an organization receive funding only from UCB, nor will we seek to exclude others from making contributions.
We engage in support of policies that recognize and reward innovation, encourage value-based care, and promote affordable access to medicines for patients, including incorporation of patient perspectives throughout discovery, development, and delivery.
We aim to build trustful relationships and have internal governance and processes to ensure continued ethical engagement with patient and provider advocacy organizations. As a global company, we comply with applicable laws and regulations governing interactions with patient and provider organizations.
We are aligned with PhRMA and BIO Principles for Interactions with Patient Advocacy Organizations.